R_3 is chosen from hydrogen, optionally substituted alkyl-, optionally substituted aryl-, optionally substituted aralkyl-, optionally substituted heteroaryl-, optionally substituted heteroaralkyl-, —C(O)—R_7, and —$S(O)_2$—R_{7a}; and R_6 is chosen from hydrogen, optionally substituted alkyl-, optionally substituted aryl-, optionally substituted aralkyl-, optionally substituted heteroaralkyl-, and optionally substituted heterocyclyl-;

or R_3 taken together with R_6, and the nitrogen to which they are bound, form an optionally substituted 5- to 12-membered nitrogen-containing heterocycle, which optionally incorporates from one to two additional heteroatoms, selected from N, O, and S in the heterocycle ring.

19. A compound according to claim 18, wherein

R_3 is —C(O)R_7;

R_6 is chosen from hydrogen, optionally substituted alkyl-, optionally substituted aryl-, optionally substituted aralkyl-, optionally substituted heteroaralkyl-, and optionally substituted heterocyclyl- and

R_7 is selected from hydrogen, optionally substituted alkyl-, optionally substituted aralkyl-, optionally substituted heteroaralkyl-, optionally substituted heteroaryl-, optionally substituted aryl-, R_8O— and R_{14}—NH—, wherein R_8 is chosen from optionally substituted alkyl and optionally substituted aryl and R_{14} is chosen from hydrogen, optionally substituted alkyl and optionally substituted aryl.

20. A compound according to any one of claims **1-4** or **9-19** wherein R_2 and R_2 are each attached to a stereogenic center having an R-configuration.

21. A composition comprising a pharmaceutical excipient and a compound, salt, or solvate thereof of any one of claims **1-19**.

22. A composition according to claim 21, wherein said composition further comprises a chemotherapeutic agent other than a compound of Formula I or a pharmaceutical salt or solvate thereof.

23. A composition according to claim 22, wherein said composition further comprises a taxane.

24. A composition according to claim 22, wherein said composition further comprises a vinca alkaloid.

25. A composition according to claim 22, wherein said composition further comprises a topoisomerase I inhibitor.

26. A method of inhibiting KSP which comprises contacting said kinesin with an effective amount of a compound according to any one of claims 1 to 19.

27. A method for the treatment of a cellular proliferative disease comprising administering to a subject in need thereof a compound according to any one of claims **1-19**.

28. A method for the treatment of a cellular proliferative disease comprising administering to a subject in need thereof a composition according to any one of claims **21-25**.

29. A method according to claim 28 wherein said disease is selected from the group consisting of cancer, hyperplasias, restenosis, cardiac hypertrophy, immune disorders, and inflammation.

30. The use, in the manufacture of a medicament for treating cellular proliferative disease, of a compound according to any one of claims **1-19**.

31. The use of a compound as defined in claim 30 for the manufacture of a medicament for treating a disorder associated with KSP kinesin activity.

* * * * *